• We are dedicated to
    the future of clinical development
    and to every life it saves.

    Learn more about why we do what we do, and what we can do for you. Click to read our story.

Social Media

See the latest interactions from our social media

Google+

With more drugs on the market than ever before, the need to demonstrate real-world evidence of product...


View Post

Featured News

Read the latest updates from our PR department

PRA Health Sciences, Inc. Announces Secondary Offering of 5,000,000 Shares of Common Stock

RALEIGH, N.C., May 02, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (the “Company”) (NASDAQ:PRAH) today announced that certain of its stockholders (the “Selling Stockholders”), intend to [...]

PRA Health Sciences, Inc. Reports First Quarter 2016 Results and Updates 2016 Guidance

$372.3 million of service revenue in the first quarter; 13.0% constant currency growth compared to the first quarter of 2015   First quarter GAAP Net Loss of $16.0 million or $0.27 per diluted share, [...]

PRA Health Sciences Named Clinical Research Company of the Year

RALEIGH, N.C., April 18, 2016 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc., (PRA) (NASDAQ:PRAH) is pleased to announce it was once again recognized as the Best Clinical Research Company of the Year. [...]

Read More >

Media Resources

Explore the latest resources uploaded to our media library

Sign Up for PRA's Industry Watch

Brought to you by PRA Health Sciences. A Bi-Weekly Industry Watch Newsletter

CASE STUDY: PRA Feasibility Leads To Unique Enrollment Strategy

PRA recently performed a feasibility study to identify investigators who see patients with a rare neuromuscular autoimmune disease and who have the capability to perform a Phase II clinical trial.

FACT SHEET: CNS

PRA Health Sciences provides our clients with innovative solutions for CNS (neurology, psychiatry, and pain) drug development. Our work spans from early phase development to NDA and MAA submissions...

CASE STUDY: PRA Teamwork Demonstrates Vision

A large pharmaceutical client selected PRA to conduct 2 Phase III epilepsy studies in India, Eastern and Western Europe, and Australia. PRA’s project teams surpassed recruitment goals and achieved timely site activations despite administrative delays and tough competition for volunteers.

Events

Find out what's happening next on PRA's event schedule

DIA CHINA
May 15 - May 18

The DIA China Annual Meeting as the largest interdisciplinary event in Asia that brings together a global network of life sciences professionals to foster innovation that leads to the development of safe and effective products and therapies to patients. Professionals at all levels involved in the drug discovery, development, and life cycle management of health […]

CZECH LIVER SOCIETY CONGRESS
May 25 - May 27

This must-attend event gathers hepatologists from The Czech Republic to exchange the latest research, discuss new developments in treatment outcomes, and network with other experts in the field.

INTERNATIONAL CONFERENCE ON OPIOIDS (ICOO) 2016
June 5 - June 7

Opioids are effective tools when used properly in the management of pain. They are cost effective and allow increased numbers of patients to return to active productive lives in society. Yet, while opioids have been with us for over 4000 years, the landscape of opioid therapies is rapidly evolving. Federal and state regulations are swiftly […]

Read More >